HCPs
New Page
患者故事
參與其中
家
Who we are
What we do
Events
早期診斷
NICE
視頻
Copy of Reports
資源
店鋪
聯繫我們
Menu
Alectinib is a 2nd generation TKI developed by Roche. The recommended dose is 600mg taken twice daily. Along with Brigatinib, Alectinib is the usual first line treatment for newly diagnosed ALK-positive lung cancer patients